The effect of Montelukast on bladder hyperactivity

The effect of Montelukast on urinary symptoms in children with bladder hyperactivity

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210212050333N1

Enrollment

Registered

2021-06-09

Start date

2021-06-30

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder. Other specified urinary incontinence

Interventions

Intervention 1: Intervention group: Monte lucast 5 mg tablets, one tablet daily for 10 days, with classic treatment. Intervention 2: Control group: receiving classical treatment alone for 10 days.

Eligibility

Sex/Gender

All

Age

3 Years to 17 Years

Inclusion criteria

Inclusion criteria: Children with bladder hyperactivity 3-17 years old

Exclusion criteria

Exclusion criteria: History of allergy to Monteluca

Design outcomes

Primary

Measure	Time frame
Frequent urination. Timepoint: Frequent urination was measured at the beginning of the study and 10 days after starting Montelukast. Method of measurement: questionnaire.;Frequent urgency incontinence. Timepoint: Measuring the incidence of urgent incontinence at the beginning of the study and 10 days after starting Montelukast. Method of measurement: questionnaire.;Frequent urinary urgency. Timepoint: Measure the frequency of urinary urgency at the beginning of the study and 10 days after starting Montelukata. Method of measurement: questionnaire.	—

Measure

Time frame

Frequent urination. Timepoint: Frequent urination was measured at the beginning of the study and 10 days after starting Montelukast. Method of measurement: questionnaire.;Frequent urgency incontinence. Timepoint: Measuring the incidence of urgent incontinence at the beginning of the study and 10 days after starting Montelukast. Method of measurement: questionnaire.;Frequent urinary urgency. Timepoint: Measure the frequency of urinary urgency at the beginning of the study and 10 days after starting Montelukata. Method of measurement: questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fatemeh Darreh

Arak University of Medical Sciences

Fatemeh-dorre@yahoo.com086 33134715-19

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026